TickerTalks
Browse all tickers →
TickerTalks›$GRAL
GRGRAL

GRAIL Inc.

$GRAL·$4.6B·Medical - Diagnostics & Research·Healthcare
$124.22-0.8%YTD+44.0%1Y+168.8%
Price updated 5m ago
GRGRAL
$GRALGRAIL Inc.
$124.22-0.79%0 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $GRAL on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

0X posts · last 7 days
No mention history yet

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $GRAL — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-09-24

The move is getting stronger, with heavier trading behind it.

GRAIL's multi-cancer blood test got FDA committee vote for premarket approval Sept 23 — a $4.6B liquid-biopsy franchise with insider Ofman selling $6M into the FDA-driven rally.

GRAL is a mid-cap liquid biopsy company (Galleri multi-cancer early-detection blood test) with pending FDA approval — Q2 revenue $40M grew 25.7% YoY, EPS -$2.56 with -389% operating margin (extreme burn).

  • Sept 23 news: 'Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval' — the specific regulatory catalyst.
  • Sept 21 news: 'GRAIL: Stock Surges As Market Digests FDA Briefing Docs - I Broadly Concur (Rating Upgrade)' — the specific sell-side upgrade.
  • Sept 21 news: 'Low False Positives and High Accuracy: FDA Document Fueling Grail Stock Surge' — the technical validation.
  • Multiple set reflects pre-commercial launch phase: PE -11.1 (small denominator), PS 28.0 (extreme on revenue), ROE -15.9%, D/E 0.04 (essentially unlevered), FCF yield -6.4%.
  • Recent EPS surprises consistently positive (+3.8%, +17.1%, +26.7%, +26.8%).
  • Consensus 2026 EPS -$9.63 with next-quarter estimate -$2.51.
  • Structural: position 87% of 52-week range (extended), volume multiplier 3.51 (extreme accumulation), beta 3.25 (extreme volatility).
  • Insider tape: Ofman (executive) sold $6.01M + $425K + M-Exempt $741K plus Freidin $383K + $672K totaling ~$8.2M into the FDA-driven strength.

Nov 11 Q3 print at -$2.51 EPS is the setup — Galleri commercial launch commentary post-FDA approval, and any commentary on payer coverage progress are the multi-quarter thesis tells.

What to watch: Nov 11 Q3 print at -$2.51 EPS — Galleri commercial launch commentary post-FDA committee approval, any commentary on payer coverage progress (Medicare, private payers), and any commentary on 2026 test-volume trajectory are the multi-quarter thesis tells. Watch for continued Ofman or executive selling (a second cluster confirms), and CareDx peer print.

On the calendar: 2026-11-11

Read the AI verdict on $GRAL

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Commercializes Galleri, a multi-cancer early detection blood test using cell-free DNA methylation sequencing.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $GRAL.

Medical - Diagnostics & Research · Healthcare

Natera's Signatera MRD test shows strongest-ever prognostic data in lung cancer, reinforcing liquid biopsy as the structural diagnostic growth driver. Lab instrument destocking resolution supports Agilent/Thermo Fisher visibility. NTRA CEO selling $545K adds minor insider overhang to otherwise positive clinical data flow.

Industry benchmark

17-name peer basket
+33.9%YTD
+63.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-14.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-338%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
28.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-15.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-10.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-2.56$-2.66+3.8%
Q1 2026May 5, 2026$-2.29$-2.76+17.1%
Q4 2025Feb 19, 2026$-2.44$-3.33+26.7%
Q3 2025Nov 12, 2025$-2.46$-3.36+26.8%
Next earningsWed, Nov 11·consensus EPS $-2.51

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$44.7M+25.7%-28.1%-389%$-2.56$-81.2M
Q1 FY26$40.8M+28.1%47.9%-333%$-2.29$-87.5M
Q4 FY25$43.6M+14.0%-25.5%-285%$-2.44$-63.0M
Q3 FY25$36.2M+26.3%-37.9%-346%$-2.46$-63.6M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$180.9M$177.9M – $183.8M-$9.63-$10.28 – -$9.048
FY27$226.8M$214.3M – $245.7M-$10.20-$10.55 – -$9.788
FY28$287.3M$245.0M – $354.4M-$9.69-$12.01 – -$8.2910
FY29$371.2M$346.9M – $406.3M-$10.33-$11.60 – -$9.455
FY30$477.7M$446.4M – $522.9M-$9.54-$10.72 – -$8.735

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.3.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.98%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+62.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+72.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 39.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today8.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β3.255-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 21Aaron FreidinCFO4.1K sh$383KSellSep 21Joshua J. OfmanCEO61.5K sh$6.0MSellAug 27Joshua J. OfmanCEO5.0K sh$425KSellAug 27Aaron FreidinCFO7.9K sh$672KSellJun 4Partridge Andrew JohnChief Growth Officer1.5K sh$91KSellApr 8Aaron FreidinCFO45.8K sh$2.3MSellApr 8Robert P RagusaCEO123.5K sh$6.2MSellApr 8Joshua J. OfmanPresident61.7K sh$3.1M
+ 13 other (12 awards · 1 exempt) in window

See when $GRAL insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 228-K — Item 5.07: Shareholder vote
3New insider — initial holdingsJun 23
8-KOfficer or director changeJun 18-K — Item 5.02: Officer or director change · Item 8.01: Other event
+ 12 other (6 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

GRAIL (NASDAQ:GRAL) CEO Joshua Ofman Sells 61,452 Sharesdefenseworld.net·2d agoOwning a Home Is Seen as a Financial Holy Grail. But What If It Isn't?wsj.com·2d agoGrail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approvalwsj.com·2d agoFDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Testprnewswire.com·2d agoFDA advisers back safety of Grail's cancer test, narrowly endorses efficacyreuters.com·2d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$ILMN$TMO$NTRA$DHR$GH$WGS
Voices on X · last 7 days

No standout posts about $GRAL on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport